Business Wire

Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new research highlighting the potential of its ...
Business Wire

Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the company will present new preclinical data ...
Seeking Alpha

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small ...
Seeking Alpha

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small ...